

## Title (en)

Basic phenyl ethers, pharmaceutical compositions containing them and the preparation of these ethers and compositions.

## Title (de)

Neue basische Phenyläther, diese enthaltende pharmazeutische Zubereitungen und die Herstellung dieser Äther und Zubereitungen.

## Title (fr)

Ethers phényliques basiques, compositions pharmaceutiques les contenant et la préparation desdits éthers et desdites compositions.

## Publication

**EP 0009683 A1 19800416 (DE)**

## Application

**EP 79103417 A 19790912**

## Priority

DE 2842759 A 19780930

## Abstract (en)

For the Contracting States : BE, CH, DE, FR, GB, IT, NL, SE 1. Basic ethers of the general formula I see diagramm : EP0009683,P12,F1 wherein G is an unsubstituted phenyl oder benzyl group or a phenyl or benzyl group which is monosubstituted or disubstituted by halogen or is alkyl with 1-6 C atoms, Z is 1-imidazolyl or 2-methyl-1-imidazolyl, A is -CH=CR\*\*1-, -CO-CHR\*\*1-, -CHOH-CHR\*\*1- or -CH2 -CHR\*\*2-, n is 1, 2 or 3, R\*\*1 is H or alkyl with 1-4 C atoms and R\*\*2 is alkyl with 1-4 C atoms, and their physiologically acceptable acid addition salts. For the Contracting State : AT 1. Process for the preparation of basic ethers of the general formula I see diagramm : EP0009683,P13,F1 dans laquelle A is -CH=CR\*\*1-, -CO-CHR\*\*1-, -CHOH-CHR\*\*1- or -CH2 -CHR\*\*2-, n is 1, 2 or 3, R\*\*1 is H or alkyl with 1-4 C atoms and R\*\*2 is alkyl with 1-4 C atoms, and their physiologically acceptable acid addition salts, characterized in that a compound of the general formula II R-Q wherein R is the group C-O- see diagramm : EP0009683,P13,F2 and Q is a radical which can be reduced to a group -A-(CH2 )n -Z, and G, Z, A and n have the meaning indicated above, is treated with a reducing agent, or in that a compound which corresponds to the general formula I but in which the hydroxyl group is present in a functionally modified form is treated with a solvolizing agent with liberation of the hydroxyl group, or in that a compound of the general formula III R-A-(CH2 )n -X wherein X is Cl, Br, I, OH or reactively functionally modified OH and R, A and n have the meaning indicated above, is reacted with a compound of the general H-Z and in that, optionally, a resulting hydroxy compound of the formula I wherein A is -CHOH-CHR\*\*1- is treated with a dehydrating agent and/or a resulting compound of the formula I wherein A is -CH=CR\*\*1-, CO-CHR\*\*1- or -CHOH-CHR\*\*1 is treated with a reducing agent and/or a resulting base of the formula is converted to one of its physiologically acceptable acid addition salts by treatment with an acid.

## Abstract (de)

Die neuen basischen Äther der allgemeinen Formel I <IMAGE> worin G eine unsubstituierte oder eine ein- oder zweifach durch Halogen substituierte Phenyl- oder Benzylgruppe oder Alkyl mit 1 - 6 C-Atomen, Z -NR<sup>1</sup>R<sup>2</sup>, 1-Imidazolyl oder- 2-Methyl-1-imidazolyl, A -CH = CR<sup>3</sup>, -CO-CHR<sup>3</sup>-, -CHOH-CHR<sup>3</sup>- oder -CH<sub>2</sub>-CHR<4>-, n 1, 2 oder 3, R<sup>1</sup>, R<sup>2</sup> und R<sup>3</sup> (gleich oder verschieden) jeweils H oder Alkyl mit 1 - 4 C-Atomen und R<4> Alkyl mit 1 - 4 C-Atomen bedeuten, insbesondere z.B. 1-(4-p-Chlorphenoxy-phenyl)-3-(1-imidazolyl)-propen, sowie ihre physiologisch unbedenklichen Säureadditionssalze besitzen wertvolle pharmakologische, insbesondere antitykotische und antibakterielle Wirkungen. Es werden mehrere Arten zu ihrer Herstellung beschrieben.

## IPC 1-7

**C07C 93/14**; **C07C 97/10**; **C07D 233/60**; **A61K 31/135**; **A61K 31/415**

## IPC 8 full level

**A61K 31/135** (2006.01); **A61K 31/415** (2006.01); **A61P 3/06** (2006.01); **A61P 7/02** (2006.01); **A61P 25/04** (2006.01); **A61P 29/00** (2006.01); **A61P 31/00** (2006.01); **C07C 67/00** (2006.01); **C07C 213/00** (2006.01); **C07C 217/56** (2006.01); **C07C 217/62** (2006.01); **C07C 217/64** (2006.01); **C07C 225/16** (2006.01); **C07D 233/60** (2006.01); **C07D 249/08** (2006.01); **C07D 521/00** (2006.01)

## CPC (source: EP)

**A61P 3/06** (2017.12); **A61P 7/02** (2017.12); **A61P 25/04** (2017.12); **A61P 29/00** (2017.12); **A61P 31/00** (2017.12); **C07C 217/62** (2013.01); **C07D 231/12** (2013.01); **C07D 233/56** (2013.01); **C07D 249/08** (2013.01)

## Citation (search report)

- DD 9565 A
- GB 787308 A 19571204 - FERROSAN AB
- US 2765307 A 19561002 - SCHMIDLE CLAUDE J
- DE 2765307 A
- US 3833603 A 19740903 - REGEL E, et al
- US 4006243 A 19770201 - STREHLKE PETER, et al

## Cited by

FR2645019A1; WO9011997A3; EP0676409B1

## Designated contracting state (EPC)

AT BE CH DE FR GB IT NL SE

## DOCDB simple family (publication)

**EP 0009683 A1 19800416**; **EP 0009683 B1 19830810**; AT E4420 T1 19830815; AU 5126579 A 19800417; AU 526323 B2 19830106; CA 1136635 A 19821130; DE 2842759 A1 19800410; DE 2966050 D1 19830915; ES 484525 A1 19800616; HU 178648 B 19820628; IL 58328 A0 19791230; JP S5551043 A 19800414; YU 237579 A 19830228; ZA 795181 B 19801231

## DOCDB simple family (application)

**EP 79103417 A 19790912**; AT 79103417 T 19790912; AU 5126579 A 19790927; CA 336319 A 19790925; DE 2842759 A 19780930; DE 2966050 T 19790912; ES 484525 A 19790927; HU ME002300 A 19790928; IL 5832879 A 19790926; JP 12426779 A 19790928; YU 237579 A 19790920; ZA 795181 A 19790928